تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $8.3B | $8.3B | $8.3B | $8.1B | $7.7B | $5.5B | $2.8B | $2.8B | $2.6B | $1.8B | $1.7B | $1.6B | $1.5B | $1.3B | $1.1B | $946M | $900M | $888M | $865M | $631M | $456M |
| سود ناخالص | $1.9B | $2.2B | $2.4B | $2.4B | $2.2B | $1.5B | $808M | $832M | $769M | $727M | $705M | $666M | $600M | $491M | $397M | $334M | $359M | $380M | $376M | $276M | $199M |
| حاشیه سود ناخالص % | 23.0% | 26.4% | 29.4% | 29.6% | 28.6% | 27.5% | 28.9% | 29.6% | 29.6% | 41.3% | 42.3% | 42.3% | 39.9% | 36.7% | 35.6% | 35.3% | 39.9% | 42.8% | 43.5% | 43.8% | 43.8% |
| سود عملیاتی (EBIT) | $857M | $1.0B | $1.1B | $956M | $795M | $379M | $392M | $433M | $373M | $338M | $312M | $282M | $202M | $121M | $72M | $39M | $92M | $107M | $100M | $69M | $48M |
| حاشیه سود عملیاتی % | 10.3% | 12.3% | 13.3% | 11.8% | 10.3% | 6.9% | 14.0% | 15.4% | 14.4% | 19.2% | 18.7% | 17.9% | 13.5% | 9.1% | 6.5% | 4.2% | 10.2% | 12.1% | 11.5% | 11.0% | 10.5% |
| سود خالص | $70M | $229M | $791M | $612M | $505M | $153M | $328M | $374M | $323M | $281M | $262M | $240M | $172M | $103M | $55M | $23M | $87M | $94M | $78M | $56M | $38M |
| حاشیه سود خالص % | 0.8% | 2.8% | 9.6% | 7.5% | 6.5% | 2.8% | 11.7% | 13.3% | 12.4% | 16.0% | 15.7% | 15.2% | 11.5% | 7.7% | 5.0% | 2.4% | 9.7% | 10.6% | 9.0% | 8.9% | 8.4% |
| EBITDA | — | $824M | $1.6B | $1.5B | $1.4B | $739M | $489M | $532M | $452M | $402M | $379M | $339M | $264M | $169M | $111M | $69M | $128M | $141M | $130M | $88M | $63M |
| سود هر سهم (EPS) | $0.89 | $2.90 | $9.53 | $7.40 | $6.13 | $2.25 | $6.15 | $6.88 | $5.90 | $5.13 | $4.65 | $3.97 | $2.73 | $1.65 | $0.91 | $0.37 | $1.44 | $1.57 | $1.30 | $1.88 | $1.33 |
| سهام منتشرشده (میلیون) | — | 79M | 83M | 83M | 82M | 68M | 53M | 54M | 55M | 55M | 56M | 60M | 63M | 62M | 61M | 61M | 61M | 60M | 60M | 30M | 29M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی ICLR در دسترس است. /companies/us/ICLR
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms